Literature DB >> 1515833

Mesalazine induced lupus-like syndrome.

M T Pent1, S Ganapathy, C D Holdsworth, K C Channer.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1515833      PMCID: PMC1883207          DOI: 10.1136/bmj.305.6846.159-b

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  2 in total

1.  Pericardial effusion during treatment with 5-aminosalicylic acid in a patient with Crohn's disease.

Authors:  H Jenss; E W Becker; P Weber
Journal:  Am J Gastroenterol       Date:  1990-03       Impact factor: 10.864

2.  Regression of atheroma.

Authors: 
Journal:  Br Med J       Date:  1977-07-02
  2 in total
  6 in total

1.  Hypersensitivity reaction to balsalazide.

Authors:  V Adhiyaman; A Vaishnavi; S Froese
Journal:  BMJ       Date:  2000-03-04

2.  Drug points: Hypersensitivity reaction to balsalazide.

Authors:  V Adhiyaman; A Vaishnavi; S Froese
Journal:  BMJ       Date:  2001-09-01

3.  Fever, vasculitic rash, arthritis, pericarditis, and pericardial effusion after mesalazine.

Authors:  A G Lim; K R Hine
Journal:  BMJ       Date:  1994-01-08

Review 4.  5-Aminosalicylic Acid-Associated Myocarditis and Pericarditis: A Narrative Review.

Authors:  Glen Brown
Journal:  Can J Hosp Pharm       Date:  2016-12-23

Review 5.  Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease.

Authors:  C J Mulder; S J van den Hazel
Journal:  Mediators Inflamm       Date:  1998       Impact factor: 4.711

6.  Coexistence of Crohn's disease and systemic lupus erythematosus: a case report and literature review.

Authors:  Xiaorong Jin; Gui Wang; Xiaohua Xu; Yunjing Bai; Ran An; Dexun Jiang
Journal:  Eur J Gastroenterol Hepatol       Date:  2020-09       Impact factor: 2.586

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.